2008 PBL Cat_mech_r.qxd:PBL Catalog.mech 11/29/07 1:50 PM Page 27
VeriKine™Mouse Toll-Like Receptor Ready ELISA
Matrix Sample
Type Compatibility Requirement Assay Range Catalog # Size
TLR3 Ready Mouse IFN-β, Cell Culture Supernatant, 100 µl 15-1000 pg/ml 42420-1 1 Plate
Colorimetric Sandwich ELISA Serum
1 Plate = 96 wells
The family of Toll-like receptors (TLRs) plays key roles
in pathogen recognition and regulation of the innate
immune response. Toll-like receptor 3 (TLR3) has been
shown to specifically recognize double-stranded RNA, a
molecular pattern associated with viral infection. TLR3
forms a complex with the adaptor molecules TRIF and
TBK that result in the phosphorylation of IRF3. The
activated IRF3 translocates to the nucleus and along
with other transcription factors like NF-κB up-regulates
the production of IFN-β. TLR3 is primarily expressed
inside the cell associated with the endosomes. Thus,
signaling by TLR3 requires intracellular delivery of the
dsRNA. Today, the most widely used dsRNA is the
synthetic polyinosinic:polycytidylic acid (poly I:C) due
to its potent activity and increased stability.
The VeriKine
TM
Mouse TLR3 Ready ELISA kit contains the
proven TLR3 dsRNA ligand, poly I:C, to initiate the TLR3
signaling, and our mouse IFN-β ELISA to monitor the
effects of poly I:C-induced expression of mouse IFN-β.
Most importantly, the kit includes detailed protocols that
allows even novice researchers to pursue this exciting
field of research. Quantitative results are obtained using a
standard microplate reader.
Whether you are searching for agonists, or performing
pathway analysis studies, choose the VeriKine
TM
Mouse
TLR3 Ready ELISA kit and focus on results rather than
assay development.
VeriKine™Mouse TNF Alpha ELISA
Matrix Sample
Type Compatibility Requirement Assay Range Catalog # Size
Mouse TNF-α, Colorimetric Cell Culture Supernatant, 100 µl 0-1250 pg/ml 42800-1 1 Plate
Sandwich ELISA Serum, and Plasma
1 Plate = 96 wells
www.interferonsource.com Tel: +1 732-777-9123
I
Fax: +1 732-777-9141
27
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62